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The purpose of this paper is to evaluate the chronic eﬀect of sitagliptin on metabolic profile, inflammation, and redox status in
the Zucker Diabetic Fatty (ZDF) rat, an animal model of obese type 2 diabetes. Diabetic and obese ZDF (fa/fa) rats and their
controls (ZDF +/+) were treated during 6 weeks with vehicle (control) and sitagliptin (10 mg/kg/bw). Glucose, HbA1c, insulin,
Total-c, TGs, IL-1β, TNF-α, CRPhs, and adiponectin were assessed in serum and MDA and TAS in serum, pancreas, and heart.
Pancreatic histology was also evaluated. Sitagliptin in diabetic rats promoted a decrease in glucose, HbA1c, Total-c, and TGs
accompanied by a partial prevention of insulinopenia, together, with a decrease in CRPhs and IL-1β. Sitagliptin also showed a
positive impact on lipid peroxidation and hypertension prevention. In conclusion, chronic sitagliptin treatment corrected the
glycaemic dysmetabolism, hypertriglyceridaemia, inflammation, and hypertension, reduced the severity of the histopathological
lesions of pancreatic endocrine and exocrine tissues, together with a favourable redox status, which might be a further advantage
in the management of diabetes and its proatherogenic comorbidities.
1. Introduction
Type 2 diabetes mellitus (T2DM) is the most common
endocrine disorder worldwide, aﬀecting more than 200
million people [1]. Pathogenesis of this disease involves
abnormalities in glucose and lipid metabolism, including
inadequate insulin secretion from pancreatic β-cells and
resistance to insulin activity (insulin resistance) [2].
Hyperglycaemia and hyperlipidaemia are the key pro-
moters, through distinct mechanisms, of reactive oxygen
species (ROS) and advanced glycation end products (AGEs)
production, which causes cell damage and insulin resistance
[3, 4]. Moreover, these high levels of glucose and lipids
stimulate pro-inflammatory cytokines, promote lipid perox-
idation, thus contributing to beta-cell degradation, particu-
larly due to apoptosis pathways [5]. Actually, inflammation
and oxidative stress play a major role in type 2 diabetes
mellitus (T2DM) pathophysiology, contributing for obesity,
insulin resistance and cardiovascular complications, which
further aggravate the disease. However, so far, there are
no therapeutic options able to eﬃciently act not only on
the glucose control but, and specially, on the prevention of
T2DM evolution and its complications, namely, by beta-cell
function preservation.
In T2DM patients, the eﬀect of the glucose-dependent
insulinotropic polypeptide (GIP), as well as the secretion
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of the glucagon-like peptide-1 (GLP-1), is diminished or
absent, contributing to insulin secretion deficiency [6]. These
two incretins are secreted by the intestine [7] and stimu-
late insulin secretion by beta-cells, in a glucose-dependent
manner [8], preventing hypoglycemia. In animal models,
continuous infusion of GLP-1 or injection of long-acting
GLP-1 mimetics, such as exendin-4, has shown a remarkable
glucose-lowering eﬃcacy, together with an ability to increase
beta-cell neogenesis and reduce apoptosis and alpha-cell
glucagon secretion [9–11]. Despite the beneficial actions of
GLP-1 and GIP, their use as antidiabetic agents (mimetics)
is impractical due to their short half-lives, as a result of
their rapid inactivation by dipeptidyl peptidase-IV (DPP-
IV) [12, 13]. Thus, orally administered DPP-IV inhibitors
have emerged as a new class of antihyperglycaemic agents
with the ability for extending the biological eﬀects of incretin
hormones through the inhibition of their degradation [14,
15], with the advantage of higher stability and bioavailability
when compared with the mimetics.
Sitagliptin, an orally available DPP-IV inhibitor devel-
oped to be used as a once daily treatment for T2DM,
has shown beneficial eﬀects on glycaemic control, reducing
HbA1c, and preventing hypoglycemia, as well as on islet
mass and function, with no relevant adverse eﬀects [16,
17]. Considering the vast physiological actions promoted
by the incretins, not only related with the control of
glucose by insulin and glucagon regulation, but also with
the peripheral insulin sensitization, cardiac and neuronal
protection and beta-cell preservation, the use of an incretin
enhancer (such as sitagliptin) might present beneficial eﬀects
on diabetes pathophysiology and on prevention of its serious
complications, which deserves better elucidation.
The male Zucker Diabetic Fatty (ZDF) rat displays
glucose intolerance, marked insulin resistance, and hyper-
lipidaemia, and becomes overtly diabetic after 8 weeks of
age if fed a diet containing 6.5% fat [18]. In the prediabetic
state, the male ZDF rat experiences a steady increase in
basal insulinaemia and plasma free fatty acid (FFA) levels.
Hyperglycemia develops between 8 and 10 weeks of age,
leading to overt diabetes and collapsing insulin secretion
[19]. This profile mimics the progressive loss of glucose-
stimulated insulin secretion in human type 2 diabetes and,
thus, the ZDF rat represents a good animal model for
studying human T2DM pathophysiology and the eﬀects of
therapeutic options [20].
The purpose of this study was, thus, to assess the eﬀects
of chronic sitagliptin treatment on the metabolic profile,
inflammation, and redox status and pancreas histology in the
ZDF rat, an animal model of obese T2DM.
2. Material and Methods
2.1. Animals and Experimental Design. Male ZDF rats
(ZDF/Gmi, fa/fa) and their littermates (ZDF/Gmi, +/+)
were purchased from Charles River Laboratories (Barcelona,
Spain) with 6 weeks of age. Rats were properly housed,
handled daily, and kept at a controlled standard temperature
(22-23◦C), humidity (60%) and light-dark cycles (12/12
hours). Throughout the experiment, the animals were fed
distilled water ad libitum and rodent maintenance chow (A-
04 Panlab, Barcelona, Spain) containing 15.4% of protein
and 2.9% of lipids). The chow was adapted to the animal’s
body weight (BW): 100 mg/g. Animal experiments were
conducted according to the European Council Directives on
Animal Care and to the National Laws.
When aged 20 weeks (T0), the diabetic ZDF (fa/fa)
rats were divided in 2 subgroups (n = 8 rats each): a
control and a treatment group, receiving, respectively, by oral
gavage, once a day (6:00 PM), during 6 weeks, the vehicle
(orange juice) and sitagliptin (10 mg/kg/BW/day). The same
procedures were adopted with the lean nondiabetic ZDF
(+/+) control rats. The ZDF (+/+) control group under
sitagliptin treatment showed no relevant diﬀerences when
compared with the ZDF (+/+) control rats under vehicle
and, thus, the results were excluded from tables and figures
in order to facilitate data comparison and interpretation.
Food intake and BW were measured each day before
treatment and expressed as weekly average values. Systolic
blood pressure (SBP), diastolic blood pressure (DBP) and
heart rate (HR) were determined in conscious rats using
a tail-cuﬀ sphygmomanometer LE 5001 (Letica, Barcelona,
Spain) in appropriate restriction cages. Pulse pressure (PP)
was calculated by the diﬀerence between the systolic and
the diastolic readings (PP=SBP−DBP). Blood pressure (BP)
values, obtained by averaging 8 to 10 measurements, were
recorded by the same person, in a similar peaceful environ-
ment. Measurements were performed at T0 and at the end of
the study (Tf) with special precautions to minimize stress-
induced fluctuations in BP, as previously described [21].
2.2. Sample Collection and Preparation. Blood: when aged 20
weeks (T0) and at the end of the experience (26 weeks -
Tf) the rats were subjected to intraperitoneal anesthesia with
a 2 mg/kg BW of a 2:1 (v:v) 50 mg/mL ketamine (Ketalar,
Parke-Davis, Lab. Pfeizer Lda, Seixal, Portugal) solution in
2.5% chlorpromazine (Largactil, Rhoˆne-Poulenc Rorer, Lab.
Vito´ria, Amadora, Portugal) and blood samples were imme-
diately collected by venipuncture from the jugular vein into
syringes without anticoagulant (for serum samples) or with
the appropriate anticoagulant: ethylene-diaminetetraacetic
acid (EDTA)-2K for Glycosylated haemoglobin (HbA1c)
measurement.
The rats were sacrificed by anesthetic overdose. The
pancreas and the heart were immediately removed, placed
in ice-cold Krebs’ buﬀer and Bock’s fixative, respectively,
and carefully cleaned of extraneous fat, lymph nodes and
connective tissue. The organs were cross-sectioned and
cryopreservated, fixed and processed for paraﬃn embedding
in accordance with subsequent analysis protocols.
2.3. Glycaemic and Lipidic Profile Assays. Serum total choles-
terol (Total-c) and triglycerides (TGs) were analysed on a
Hitachi 717 analyser (Roche Diagnostics) using standard
laboratorial methods. Total-c reagents and TGs kit were
obtained from bioMe´rieux (Lyon, France). Serum glucose
levels were measured using a Glucose oxidase commercial
kit (Sigma, St. Louis, Mo, USA). Considering the variability
of serum glucose levels in the rat, glycosylated haemoglobin
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Table 1: Body weight, lipid profile and blood pressure in the control and diabetic ZDF rats at the initial and final time (6 weeks of vehicle or
sitagliptin treatment).
Initial Time (20 wks) Final Time (26 wks)
Control ZDF (+/+) Diabetic ZDF (fa/fa) Control ZDF (+/+) Diabetic ZDF (fa/fa)
Groups (n = 16) (n = 16) Vehicle (n = 8) Vehicle (n = 8) Sitagliptin (n = 8)
BW (g) 406.70± 6.83 388.10± 8.87 445.70± 8.16 354.40± 8.85aaa 380.00±14.46
Total-c (mg/dl) 77.50± 1.50 155.50± 3.50aaa 93.00± 2.96 193.00± 9.79aaa 193.10±4.62
TGs (mg/dl) 115.00± 11.00 374.50± 4.95a 154.00± 19.14 400.20± 27.00aaa 237.10± 22.54bbb
Systolic (mmHg) 115.50± 0.83 125.20± 0.27 116.00± 2.52 127.80± 1.23a 101.60± 0.78bbb
Diastolic (mmHg) 100.98± 0.82 91.46± 0.83 103.50± 1.94 112.70± 3.98 94.86± 0.70bbb
Mean (mmHg) 104.25± 0.25 108.20± 1.42 104.30± 4.25 117.40± 3.04a 96.86± 0.51bbb
Pulse P (mmHg) 14.52± 0.98 33.74± 0.37 14.00± 4.16 15.09± 3.08 6.71± 1.11b
BW, body weight; P, pressure; SITA, sitagliptin; Total-c, Total-cholesterol; TGs, triglycerides; ZDF, Zucker diabetic fatty. Values are means ± SEM of n rats.
Comparisons between groups: a - ZDF (fa/fa) versus ZDF (+/+) and b - sitagliptin versus vehicle; P < .05, P < .01 and P < .001 for one, two or three letters,
respectively.
(HbA1c) levels were used as an index of glucose control,
through the DCA 2000+ latex immunoagglutination method
(Bayer Diagnostics, Barcelona, Spain). Plasma insulin levels
were quantified by using a rat insulin Elisa assay kit from
Mercodia (Uppsala, Sweden). Insulin sensitivity of individual
animals was evaluated using the previously validated home-
ostasis model assessment (HOMA) index [21]. The formula
used was as follows: [HOMA-IR] = fasting serum glucose
(mmol/l) x fasting serum insulin (μU/ml)/22.5. The values
used (insulin and glucose) were obtained after an overnight
of food deprivation.
2.4. Inflammatory Profile and Redox Status. Serum levels of
interleukin-1β (IL-1β), tumour necrosis factor α (TNF-α)
and adiponectin were all measured by rat-specific Quan-
tikine ELISA kits from R&D Systems (Minneapolis, USA).
High-sensitive C-reactive protein (CRPhs) was determined
by using a rat-specific Elisa kit from Helica Biosystems Inc.
(Fullerton, CA, USA). All assays were performed according
to the manufacturers’ recommendations, in duplicate.
The thiobarbituric acid reactive-species (TBARs) assay
was used to assess serum, pancreas and heart products of
lipid peroxidation, via malondialdehyde (MDA), accord-
ing to that previously described in [22]. Samples were
analysed spectrophotometrically at 532 nm using 1,1,3,3-
tetramethoxypropane as external standard. The concentra-
tion of lipid peroxides (in MDA) was expressed as μmol/l in
the plasma and as μmol/g tissue in the pancreas and heart.
Ferric reducing antioxidant potential (FRAP) assay was used
to estimate serum total antioxidant status (TAS) [23].
2.5. Histological Studies. Specimens were paraﬃn-embedded
and the 3 μm thick sections stained for routine histopatho-
logical diagnosis with haematoxylin and eosin (HE). All
samples were examined by light microscopy using a Micro-
scope Zeiss Mod. Axioplan 2. The degree of injury visible
by light microscopy was scored in a single-blind fashion
by the pathologist to the animal study group. Endocrine
pancreatic damage was assessed by evaluating changes in
the islets of Langerhans, namely the shape (architecture),
presence of inflammatory infiltrate, fibrosis, vacuolization
and intraislets congestion. A semiquantitative rating for
each slide ranging from 0 (minimal) to 3 (severe and
extensive damage) was assigned to each component. The
exocrine pancreatic damage was evaluated, according to the
presence of congestion, fibrosis, and inflammatory infiltrate
in the interstitial tissues and graded, also, in the same
semiquantitative rating.
2.6. Statistical Analysis. Results are shown as mean ±
standard error of the mean (SEM). The comparison of values
between groups was performed by using ANOVA followed by
the Bonferroni post hoc test, through appropriate software
(GraphPadPrism 5.0 from GraphPad Software Inc., La Jolla,
CA, USA). Significance was accepted at a P less than .05.
3. Results
3.1. Eﬀects of Chronic Sitagliptin Treatment on Body Weight
and Glycaemic and Lipidic Profiles. Concerning the body
weight, no significant diﬀerences were encountered between
the diabetic and the lean control rats in the beginning
of treatments (T0: week 20), despite the obese profile
encountered in the diabetic ZDF (fa/fa) rats between the 8th
and the 14th week (data not shown). At the end of the study
(26 weeks), the control diabetic ZDF (fa/fa) rats exhibit an
8.7% reduction in their BW (P < .001); nevertheless, the lean
control group gained weight. Sitagliptin treatment, during 6
weeks, stabilized the loss of weight in the diabetic ZDF (fa/fa)
rats, even preventing part of the BW loss when compared
with the rats without treatment (Table 1).
The determination of serum glucose, HbA1c, Total-c and
TGs concentrations was carried at the initial time (T0: 20
weeks old) and at the end of the study (Tf: 26 weeks old).
At the T0, the diabetic group showed a hyperglycaemic and a
hyperlipidemic profile, also seen at the final time (Figure 1(a)
and Table 1). As illustrated in Figure 1(b), the HbA1c values
were higher in the diabetic rats than those of the control
animals, confirming the glycaemic deregulation. The diabetic
ZDF (fa/fa) rats have also presented higher levels of Total-c
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Figure 1: Glycaemic and insulinaemic profiles. Serum Glycaemia (a), HbA1c (b), insulinaemia (c) and insulin resistance (HOMA-IR) index
(d), for the control (+/+) and diabetic (fa/fa) ZDF rats, in the initial and final times (6 weeks of vehicle or 10 mg/kg BW/day sitagliptin
treatment). Comparisons between groups (n = 8 each): a - ZDF (fa/fa) versus ZDF (+/+) and b - with sita versus without sita; P < .05,
P < .01 and P < .001 for one, two or three letters, respectively. HOMA-IR, homeostasis model assessment—insulin resistance.
and TGs versus the control ZDF (+/+) animals, in both times
(Table 1).
After 6 weeks of sitagliptin treatment (Tf: 26 weeks), a
significant improvement in glycemic control was observed
in diabetic ZDF (fa/fa) rats (486.3 ± 19.1 mg/dl), when
compared with the vehicle-treated diabetic animals (523.3 ±
15.6 mg/dl; P < .001) (Figure 1(a)). This pattern of changes
is also expressed by the HbA1c levels, which decreased by
11.1% in sitagliptin-treated ZDF (fa/fa) rats when compared
with the diabetic rats not treated with the drug (Figure 1(b)).
TGs were significantly reduced (50%; P < .001) in the
diabetic rats treated with sitagliptin during 6 weeks versus
the diabetic vehicle-treated group (Table 1).
3.2. Eﬀects of Chronic Sitagliptin Treatment on Insulin Levels
and Insulin Resistance (HOMA-IR). At the beginning of
the study (T0), insulin levels were higher in the diabetic
rats than those of the control, but the diﬀerences did not
reach statistical significance. At the final time, the vehicle-
treated ZDF (fa/fa) rats exhibit relative insulinopenia (0.75±
0.05μg/l), when compared to vehicle-treated ZDF (+/+)
(1.05±0.30μg/l) (Figure 1(c)), accompanied by a significant
augment (P < .001) of insulin resistance (HOMA-IR
index) (Figure 1(d)). The elevation of insulin resistance was
prevented (P < .001) in the sitagliptin-treated diabetic (fa/fa)
rats (Figure 1(d)).
3.3. Eﬀects of Chronic Sitagliptin Treatment on Blood Pressure.
The vehicle-treated ZDF (fa/fa) group showed significantly
(P < .05) higher levels of systolic and mean BP, together with
a trend to higher diastolic and pulse pressure, when com-
pared with the vehicle-treated ZDF (+/+) group. Sitagliptin
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Figure 2: Serum inflammatory markers. Serum CRPhs (a), IL-1β (b), TNF-α (c) and Adiponectin (d) for the control (+/+) and diabetic
(fa/fa) ZDF rats, in the initial and final times (6 weeks of vehicle or 10 mg/kg BW/day sitagliptin treatment). Comparisons between groups
(n = 8 each): a - ZDF (fa/fa) versus ZDF (+/+) and b - with sita versus without sita; P < .05, P < .01 and P < .001 for one, two or three
letters, respectively. CRPhs, high-sensitive C-reactive protein; IL-1β, interleukin-1beta; TNF-α, Tumor necrosis factor-alpha.
treatment has significantly prevented the blood pressure rise
(hypertension) in the diabetic rats (Table 1).
3.4. Eﬀects of Chronic Sitagliptin Treatment on Inflammatory
Profile. Concerning the serum CRPhs levels, no significant
diﬀerences were observed between the diabetic ZDF (fa/fa)
and the nondiabetic ZDF (+/+) vehicle-treated groups
(Figure 2(a)). However, there was higher serum levels of IL-
1β and TNF-α and reduced of adiponectin in the vehicle-
treated diabetic ZDF (fa/fa) rats when compared with the
vehicle-treated nondiabetic (+/+) rats (Figures 2(b), 2(c) and
2(d)). Sitagliptin treatment has significantly decreased the
levels of CRPhs (P < .001) and IL-1β (P < .05) in the diabetic
ZDF rats (Figures 2(a) and 2(b)). However, the diabetic
(fa/fa) animals under stagliptin therapy showed, at the end
of the study, elevated (P < .01) levels of TNF-α (Figure 2(c)),
without significant changes on serum adiponectin contents
(Figure 2(d)).
3.5. Eﬀects of Chronic Sitagliptin Treatment on Serum and
Tissue Redox Status. The vehicle-treated diabetic ZDF (fa/fa)
group exhibited significantly higher levels of serum MDA (at
the T0 and Tf), accompanied by a compensatory elevation
of TAS in the final time (Figures 3(a) and 3(b)). Sitagliptin
treatment during 6 weeks has decreased (P < .01) serum TAS
content, whereas there were no diﬀerences in serum MDA
levels (Figures 3(a) and 3(b)). On the contrary, we observed
a significant reduction of pancreas (P < .001) and heart
(P < .001) MDA levels in the sitagliptin-treated diabetic ZDF
(fa/fa) rats when compared with the vehicle-treated (fa/fa)
rats (Figures 3(c) and 3(d)).
3.6. Eﬀects of Chronic Sitagliptin Treatment on Pancreatic His-
tology. In the control rats (ZDF (+/+) under vehicle treat-
ment, there was no pathological changes in the endocrine
and exocrine pancreas (Figure 4(a)). Langerhans islets of
diabetic ZDF animals treated with sitagliptin presented a
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Figure 3: Serum and tissue redox status markers. Serum MDA (a) and TAS (b) and pancreas (c) and heart (d) MDA, for the control (+/+)
and diabetic (fa/fa) ZDF rats, in the initial and final times (6 weeks of vehicle or 10 mg/kg BW/day sitagliptin treatment). Comparisons
between groups (n = 8 each): a - ZDF (fa/fa) versus ZDF (+/+) and b - with sita versus without sita; P < .05, P < .01 and P < .001 for one,
two or three letters, respectively. MDA, malondialdehyde; TAS, total antioxidant status.
diminution in fibrosis intensity (Figure 4(c)). While vehicle-
treated diabetic ZDF (fa/fa) rats presented a higher number
of animals in advanced degrees of fibrosis severity (75.0%
of grade 3; 12.5% of grade 2 and of 12.5% grade 1), in the
sitagliptin-treated group the severity of fibrosis rating ranged
only from 1 to 2 (37.5% and 62.5%, resp) (Figures 4(a)
and 4(b)). An amelioration of the inflammatory infiltrate in
the endocrine pancreas was encountered when the diabetic
ZDF rats were cronically treated with sitagliptin (Table 2).
The treated group presented 87.5% rats with grade 1 inflam-
matory infiltrate, whereas in the vehicle-treated group all
rats presented inflammatory infiltrate (37.5% of grade 3 and
62.5% of grade 2). Intra-islet cellular grade 2 vacuolation was
present in most of the rats (75%) without treatment (vehicle-
treated group). This grade was quantitatively reduced in the
treated group, in which only 1 rat (12.5%) presented grade
2 vacuolation, representing the remainder (37.5%) a grade 1
vacuolation. Congestion aﬀected one vehicle-treated diabetic
ZDF (fa/fa) rat, being completely absent in the sitagliptin
group (Table 2). Nevertheless, on the parenchymal structure
or islet size, only subtle diﬀerences were broadly detected.
All the diabetic ZDF (fa/fa) rats without stagliptin
treatment exhibited in the exocrine pancreas a variable
degree of fibrosis and ductal hypertrophy rating in levels 1,
2 and 3, as shown in Table 2 (Figures 4(d) and 4(e)). All the
rats presented inflammatory infiltrate rating from 1 (37.5%)
to 2 (62.5%). A grade 2 congestion was observed in most
of the vehicle-treated rats (75.0%). Lesions of the exocrine
pancreas of diabetic rats chronically treated with sitagliptin,
when compared with those without treatment, exhibited a
decrease in fibrosis, being absent in most of the animals
(62.5%), with the remaining cases showing fibrosis rating in
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Figure 4: Pancreatic histology at the end of experimental period. Endocrine pancreas (a, b and c): (a) Typical islet from control ZDF
(+/+) rats under vehicle treatment, without changes in the endocrine and exocrine pancreas; (b) Extensive fibrosis, vacuolation and loss of
architecture in diabetic ZDF (fa/fa) rats under vehicle treatment; (c) Diminution in fibrosis intensity and vacuolation in Langerhans islet
from diabetic ZDF (fa/fa) rats treated for 6 weeks with 10 mg/kg BW/day of sitagliptin, between weeks 20 and 26 (final time); Exocrine
pancreas (d, e and f): (d) Severe fibrosis (III) with neocanaliculi (original magnification x 200) and (e) Congestion and intense inflammatory
infiltrate from diabetic ZDF (fa/fa) rats treated with vehicle; (f) Marked decrease in fibrosis severity from diabetic ZDF (fa/fa) rats treated
with sitagliptin. hematoxylin and eosin staining (original magnification x 400).
grade 1 and 2 (Figure 4(f)). Despite the presence of grade 1
or 2 (each representing 50%) inflammatory infiltrate in all
rats, a reduction in severity was found in one of the animals
(Table 2). The severity of congestion suﬀered a decrease from
level 2 to level 1 in 50% of the rats and was completely absent
in the other 50% of the group.
4. Discussion
Previous reports suggest that local and systemic low-grade
inflammation and oxidative stress, which are mainly fuelled
by hyperglycaemia and hyperlipidaemia, are important
mediators of beta-cell degradation, insulin resistance and
T2DM complications in many individuals [24–26]. It is now
recognized that adipocytes, particularly those located within
the visceral fat, are major secretors of both pro-and antiin-
flammatory factors, often referred to as adipokines [27, 28].
Several well-known markers of inflammation secreted by the
adipose tissue, including IL-6 (which stimulated the hepatic
synthesis of CRP), IL-1β and TNF-α, have been referred as
independent predictors of diabetes [28–30]. Adiponectin, an
adipokine, has demonstrated antiinflammatory properties,
protection against insulin resistance, as well as against the
development of atherosclerosis [31–34].
In this study, we assessed the eﬀects of chronic sitagliptin
treatment on glucose and lipids deregulation and on other
cardiometabolic risk factors in an animal model of obese type
2 diabetes mellitus, the ZDF rat. Since the diagnosis of the
disease is frequently late, when diabetes pathophysiological
mechanisms are already advanced and the complications
have already been initiated, we chose to use the diabetic ZDF
rats in an established diabetes stage, which, according to our
previous data, is when the animals aged 20 weeks [35, 36].
Concerning the ZDF model of type 2 diabetes, our
results have demonstrated the key features encountered in
type 2 diabetes patients. Therefore, at the beginning of
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Table 2: Number of rats exhibiting the diﬀerent pathology scores observed in endocrine (A) and exocrine (B) pancreas.
A-Endocrine pancreas lesions
Evaluated Inflammatory Fibrosis Intra islet Congestion
parameters Infiltrate Vacuolation
Score 0 1 2 3 0 1 2 3 0 1 2 3 0 1 2 3
Groups (n = 8, each)
ZDF (+/+) vehicle 7 1 0 0 6 2 0 0 8 0 0 0 8 0 0 0
ZDF (fa/fa) vehicle 0 0 5 3 0 1 1 6 2 0 6 0 7 0 1 0
ZDF (fa/fa) sitagliptin 1 7 0 0 0 5 3 0 4 3 1 0 8 0 0 0
B – Exocrine pancreas lesions
Evaluated Inflammatory Fibrosis Congestion
parameters Infiltrate
Score 0 1 2 3 0 1 2 3 0 1 2 3
Groups (n = 8, each)
ZDF (+/+) vehicle 8 0 0 0 7 1 0 0 8 0 0 0
ZDF (fa/fa) vehicle 0 3 5 0 0 3 3 2 2 6 0 0
ZDF (fa/fa) sitagliptin 0 4 4 0 6 1 1 0 4 4 0 0
ZDF, Zucker diabetic fatty.
the study (initial time: 20 weeks of age) the diabetic rats
presented hyperglycaemia, hypercholesterolaemia, hyper-
triglyceridaemia, increased HbA1c and hyperinsulinaemia,
accompanied by insulin resistance (HOMA-IR). Insulin
levels of ZDF (fa/fa) rats were already decreased when
compared with the controls, indicating an impaired insulin
secretion by the pancreatic beta-cell. Furthermore, the ZDF
(fa/fa) rats presented obesity between the 8th and the 14th
week of age (data not shown), but started losing weight
until the week 20. This BW decrease continued throughout
the experimental period, which might be viewed as a
complication of diabetes. Furthermore, the ZDF diabetic rats
also presented, when compared with the nondiabetic ZDF
(+/+) controls, a pro-inflammatory profile, represented by
the reduced content of the antiinflammatory adipokines,
adiponectin, and the increased level of the pro-inflammatory
cytokines IL-1β and TNF-α. However, we should identify two
surprising aspect encountered in the diabetic ZDF (fa/fa)
rats at 20 weeks-old, which contrasts with previous data
from us concerning the characterization of this animal of
obese type 2 diabetes [35, 36], that were related to the
almost unchanged serum CRPhs levels between the diabetic
and the control (nondiabetic) animals and the only slightly
(but significantly) lower adiponectin in the ZDF diabetic
rats, suggesting that inflammation at this point (week 20)
was more closely related with other players (such as TNF-
α and IL-1β) and, as well, that the BW loss (which might
represent an pathophysiological aggravation of the disease)
might change the pattern of the inflammatory profile.
At the end of the experience, week 26, the ZDF rats aggra-
vated their diabetic state, viewed by a higher hyperglycaemia,
accompanied by increased HbA1c, insulin resistance and
reduced plasma concentration of insulin, suggesting that the
relative insulinopenic state, which started at the beginning
of the study, was aggravated. Moreover, the ZDF diabetic
rats continue to lose weight and showed an aggravated
hypercholesterolaemia, hypertriglyceridaemia, together with
inflammation and hypertension. At this time, however,
the increased serum MDA content was accompanied by a
compensatory increase in serum TAS, which might explain
the unchanged values of tissue (pancreas and heart) MDA
between the diabetic and nondiabetic animals. In any case,
between the week 20, corresponding to an established
diabetes state, and the week 26, the diabetic rats aggravates
the disease (viewed mainly by the aggravated hyperglycaemia
and the insulinopenia) and its complications (hypertension),
which is in agreement with our previous data concerning the
metabolic characterization of this model of type 2 diabetes
mellitus (the ZDF rat) [35, 36].
During the course of the study, the diabetic rats treated
once a day with an incretin enhancer, the DDP-IV inhibitor
sitagliptin, showed a remarkable beneficial eﬀect on sev-
eral important parameters, not only those related to the
glycaemic control, as should be expected when using an
antihyperglycaemic agent, but also on other cardiometabolic
perturbations and complications related to diabetes. There-
fore, chronic sitagliptin treatment has promoted a reduc-
tion of glucose and HbA1c levels, together with a partial
correction of insulin reduction and an improvement of
insulin resistance (HOMA-IR), which is in agreement with
other reports [37, 38]. Furthermore, the reduction of BW
was prevented and the hypertriglyceridaemia corrected,
which was accompanied by a prevention of diabetes-induced
hypertension, as previously suggested by other authors in
[38, 39]. Future studies from us will estimate the eﬀects of
this DPP-IV inhibitor on the enzyme activity/expression, as
well as on levels of GLP-1 and glucagon, in order to have a
more detailed picture of how the incretins pathway is aﬀected
and its relative contribution for the eﬀects of sitagliptin here
reported.
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Evaluation of endocrine pancreatic tissue suggests ame-
lioration in Langerhans islets by sitagliptin treatment. In
the exocrine pancreas an improvement in sitagliptin-treated
rats was also observed. However, results must be carefully
interpreted because they superimpose on those lesions
presented by diabetic rats without treatment as result of
obesity and/or type 2 diabetes. Matveyenko et al. (2009)
using HIP rats reported beneficial eﬀects of sitagliptin in
endocrine pancreas, together with haemorrhagic pancreatitis
in one sitagliptin treated rat, ductal metaplasia in three
sitagliptin-treated rats and increased ductal proliferation in
all sitagliptin-treated rats, suggesting chronic pancreatitis
[40]. Nevertheless, they use a dosage 20 fold larger, with
a duration of treatment twice longer than the one used
in our present work. Despite the diﬀerence in rat specie,
dose and route of administration, the studies of Matveyenko
et al. (2009), using a DPP IV inhibitor, and of Nachnani
et al. (2010) [41], using an injection of GLP-1 agonist
to enhance endogenous GLP-1 levels, raise the possibility
that the enhancement of endogenous GLP-1 levels could
induce undetected low grade asymptomatic chronic pancre-
atitis. Despite the lower dose used, we observed beneficial
eﬀects of sitagliptin on metabolic profile and reduction in
inflammatory markers, as well as an amelioration of fibrosis,
vacuolization and congestion in endocrine pancreas. Others
have observed similar results using FE 999011, an inhibitor
of DPP IV, administrated orally in a dose of 10 mg/kg BW
once a day [42]. The therapeutic dosage required to improve
glucose tolerance, on an acute scale in humans (0.2 mg/kg),
is 200-fold lower than the one used in the present study
[43]. Our findings suggest that the compensatory change
in circulating DPP-IV levels could be avoided by once-daily
treatment and/or a lower inhibitor dosage.
Concerning the markers of inflammation and oxidative
stress, this study demonstrated an important eﬀect of
sitagliptin on CRPhs and IL-1β serum levels, reducing the
higher levels encountered in the diabetic rats. The eﬀects on
these mechanisms have contrasted with those encountered
on TNF-α and adiponectin, in which an increment and the
absence of influence, respectively, were observed, suggesting
that distinct mechanisms regulates the diﬀerent cytokines
produced by the adipocyte tissue. The increment on serum
TNF-α levels might eventually suggest undesirable side eﬀect
of sitagliptin. Therefore, it is well known that the inhibition
of the serine protease DPP-IV in type 2 diabetes treatment
prevents its activation of insulin-releasing peptide hormones.
However, DPP-IV also cleaves many other molecules, includ-
ing chemokines, suggesting that inhibition of this enzyme
could have undesired side eﬀects and might be responsible
for allergic reactions and runny or stuﬀy nose, sore throat,
and upper respiratory infection, described as sitagliptin side
eﬀects [44].
The beneficial eﬀect on systemic CRPhs and IL-1β was
accompanied by an improvement of tissue redox status, with
a remarkable positive impact on lipid peroxidation in both
the pancreas and the heart. These eﬀects, together with a
decrease in TGs content, might contribute to reduce pan-
creatic beta-cell deterioration, which is a feature of diabetes
evolution to high deregulated states, and to alleviate the
cardiovascular complications that accompany the evolution
of the disease and that are responsible for the associated high
mortality and morbidity rates worldwide [45]. The blood
pressure amelioration found in our study might be secondary
to the improvement of glucose and lipidic dysmetabolism,
low-grade inflammation and oxidative stress status, which
are factors undoubtedly linked with the cardiometabolic
complication associated with diabetes. However, a direct
favourable influence of sitagliptin on the cardiovascular
system might occur, as suggested by the positive impact
on heart redox status. Furthermore, the previously sug-
gested antiapoptotic eﬀect of the incretin modulators on
the pancreas might be extended to other tissues, such as
the heart. This hypothesis should be further reinforced in
future studies. An adequate treatment for type 2 diabetes,
according to the guidelines, should be focused not only on
glycaemia control, but also, on reduction of triglycerides
and blood pressure, thus preventing the cardiovascular
complications [46–48]. According to previous data, there
is yet no suﬃcient clinical data to assess the real influence
of incretin modulators on cardiovascular disease prevention
and on long-term cardiovascular safety [49, 50].
Several reports have indicated that DPP-IV inhibitors are
as antihyperglycaemic as any other oral antidiabetic drugs,
with the additional benefit of not promoting hypoglycaemia
and weight gain [45]. Further studies, using another antidi-
abetic agent from other group, should be performed in
order to confirm if the beneficial eﬀects now obtained are
clearly directly attributed to the mechanism of action of
this compound and are not exclusively resulting from the
improvement of glycemic control. Since GLP-1 receptors
have been identified in several tissues related with the car-
diovascular system, such as the cardiomyocytes and vascular
endothelial cells, the eﬀects of the incretin-based therapies,
such as the DPP-IV inhibitors, point to a potential benefit
on attenuation of type-2 diabetes-induced cardiovascular
complication [45]. However, the current limitations are
related to the lack of log-term clinical studies [49, 50]. In any
case, considering the interesting properties demonstrated by
these new class of antidiabetic agents, which make them
diﬀerent from the traditional drugs, and if the clinical
studies are able to confirm other influences, apart the already
reported glycaemic control and HbA1c reduction, in a near
future their place in the treatment algorithm might be
reviewed. Therefore, if the beneficial eﬀects on beta-cell
function preservation, as well as on prevention of diabetic
complications, will be further confirmed, they might be
recommended not only as adjuvant therapy when other
antidiabetics fail to control glycaemia and HbA1c levels,
but also, as one of the main choices for type 2 diabetes
management and prevention of complications.
5. Conclusions
This study, using a model of obese T2DM (the ZDF
rat), demonstrated that chronic inhibition of DPP-IV by
sitagliptin can correct the glycaemic dysmetabolism, hyper-
triglyceridaemia, inflammation and hypertension, reduce
severity of histopathological lesions of endocrine and
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exocrine pancreas, jointly, with a favourable influence on
the pancreas and heart lipid peroxidation, which have been
identified as the key pathophysiological mechanism underly-
ing insulin resistance, beta-cell degradation and associated
micro-and-macrovascular complications. These influences
here reported may become further advantages in the thera-
peutics of type 2 diabetes and in the prevention/management
of its pro-atherogenic macrovascular complications.
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